Coral Laboratories Ltd Stock Price Today (NSE: CORALAB)

Coral Laboratories Ltd

506.30+6.20 (+1.24%)
Market Closed

Fundamental Score

...

Coral Laboratories Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Coral Laboratories Ltd share price today is 506.30, up +1.24% on NSE/BSE as of 22 June 2026. Coral Laboratories Ltd (CORALAB) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 175.62 (Cr). The 52-week high for CORALAB share price is 624.95 and the 52-week low is 360.00. At a P/E ratio of 9.95x, CORALAB is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 13.06% and a debt-to-equity ratio of 0.00.

Coral Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
516.30
Low
410.00
Volume
966.2727272727273
Change
+11.83%

Coral Laboratories Ltd share price chart: 11.83% return over the past month. 52-week high ₹624.95, 52-week low ₹360.00.

Coral Laboratories Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
475.00524.70475.00506.301.18K (Cr)
526.00528.00486.00500.102.50K (Cr)
486.60489.00466.20473.05262.00 (Cr)
500.00500.00470.00474.70424.00 (Cr)
490.15502.95490.15492.85209.00 (Cr)
470.00516.30465.00499.404.06K (Cr)
468.00476.60444.00465.70531.00 (Cr)
490.00490.00455.20469.35288.00 (Cr)
463.95467.90442.05456.75938.00 (Cr)
460.70468.00443.25457.65550.00 (Cr)

Coral Laboratories Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
526.00528.00475.00506.30-3.75%
427.70516.30411.10473.05+10.60%
392.45445.00373.10424.95+8.28%
434.00472.95360.00370.55-14.62%
436.60496.00420.10443.70+1.63%
458.95496.60415.00434.65-5.29%
494.90504.70429.00438.50-11.40%
511.90532.80482.50490.20-4.24%
478.00545.00478.00509.40+6.57%
452.73543.37447.74489.15+8.05%
578.00594.85441.31444.75-23.05%
597.10624.95560.70575.35-3.64%

AI Research Briefing

Powered by Gemini · 2026-04-09

Micro-cap pharma play hoping for a turnaround, but financials are deteriorating; avoid until clear signs of improvement.

Research Confidence
4.0/10Low
MICRO-CAP DARK HORSEBreakdown, 1M: -3.43%, 3M: -1.16%, 6M: -17.33%.Cheap, P/E of 9.95x vs. industry P/E of 31.77x.

WHAT'S HAPPENING NOW (last 2-4 weeks)

Coral Laboratories completed capacity expansion at its Dehradun plant. The board re-appointed Mr. Malay Doshi as an Independent Director. Markets Mojo downgraded the stock to a 'Strong Sell'. The stock hit a fresh 52-week low of on March 27, 2026.

CORE STORY (THE REAL GAME)

Why Now
  • Capacity expansion completed
  • Low valuation relative to industry
  • Bearish technical indicators
Potential Catalysts
  • Successful capacity utilization
  • Improved quarterly results
  • Positive analyst upgrades
Key Risks
  • Micro-cap liquidity risk
  • Four consecutive quarters of negative results
  • Declining sales and profit
  • Strong Sell rating
Institutional Activity

No significant FII/DII activity. Promoter holding stable at 71.51%.

Macro Context

Indian pharma sector projected to grow to $130 billion by 2030, but faces global pricing pressures.

Order Book / Expansion

Dehradun plant capacity expansion completed.

Cash Flow Quality

Poor, Free Cash Flow 5Y: ₹0.21 Cr.

3–6 Month Outlook

Next 3-6 months hinge on the company's ability to translate capacity expansion into improved sales and profitability. Failure to do so will likely result in further price decline.

Primary Thesis Risk

Inability to translate capacity expansion into improved financials.

For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.

Returns & Performance

Poor

Return on Equity (ROE)

13.06%

Profit generated per ₹1 of shareholder equity

Good

Return on Capital (ROCE)

17.44%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

15.67%

Average operating profit margin over 5 years

Dividend Yield

0.30%

Annual dividend as % of current share price

Coral Laboratories Ltd Valuation Check

Excellent

Price to Earnings (P/E)

9.95x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

31.77x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

71.51%

% shares held by company founders/management

Poor

FII Holding

0.00%

% shares held by foreign institutional investors

Poor

DII Holding

0.00%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-12.70%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

-40.96%

Revenue growth vs same quarter last year

Average

Revenue Growth (5-Year CAGR)

10.26%

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

28.24%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

28.24%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.00x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

109.00x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

0.21 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Coral Laboratories Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of CORALAB across key market metrics for learning purposes.

Positive Indicators

9 factors identified

Excellent ROCE Performance (17.44%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Strong Operating Margins (15.67%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages.

Attractive Valuation (P/E: 9.95 vs Industry: 31.77)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity.

Excellent EPS Growth (28.24% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential.

Strong Profit Growth Track Record (28.24% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Debt-Free Balance Sheet (D/E: 0.00)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (109.00x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Balanced Promoter Holding (71.51%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

2 factors identified

Profit Decline Concern (-12.70%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes.

Revenue Contraction (-40.96%)

Observation: Sales decline may indicate market challenges or competitive pressures.

Analysis: Negative revenue growth requires analysis of market conditions.

Coral Laboratories Ltd vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Coral Laboratories Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
55/100
506
₹175.62
9.9
Average
13.06%
Average
17.44%
Good
0.0
Excellent
28.24%
Excellent
10.26%
Good
0.30%
65.2/100
1844
₹433738.68
37.6
Average
16.86%
Good
20.21%
Excellent
0.1
Excellent
23.78%
Excellent
9.87%
Good
0.89%
67.9/100
6798
₹170445.88
68.6
Average
15.35%
Good
20.44%
Excellent
0.0
Excellent
10.41%
Good
11.65%
Good
0.47%
65.3/100
4538
₹126430.62
58.4
Average
26.52%
Excellent
27.05%
Excellent
0.3
Excellent
13.84%
Good
7.72%
Good
0.86%
Cipla Ltd...
CIPLA500087
59/100
1418
₹123059.76
22.6
Average
17.77%
Good
22.72%
Excellent
0.0
Excellent
28.68%
Excellent
9.97%
Good
0.85%
59.2/100
1319
₹105224.96
18.2
Average
17.96%
Good
22.69%
Excellent
0.2
Excellent
22.28%
Excellent
13.26%
Good
0.63%
Lupin Ltd...
LUPIN500257
66.7/100
2276
₹95148.15
22.0
Average
20.62%
Excellent
21.30%
Excellent
0.3
Excellent
54.88%
Excellent
8.11%
Good
0.58%
68.7/100
957
₹94253.78
18.7
Average
21.21%
Excellent
24.31%
Excellent
0.4
Excellent
25.92%
Excellent
10.27%
Good
1.17%
50.6/100
2420
₹92012.53
52.6
Average
14.68%
Average
15.98%
Good
0.6
Good
11.73%
Good
15.79%
Excellent
0.04%
28.8/100
1436
₹70798.69
20.7
Average
11.08%
Average
14.18%
Average
0.2
Excellent
3.87%
Average
6.55%
Good
0.33%
59.5/100
5452
₹67075.29
28.5
Average
19.39%
Good
20.38%
Excellent
0.2
Excellent
13.93%
Good
9.21%
Good
0.80%

Coral Laboratories Ltd PE Ratio History

Historical price-to-earnings ratio for CORALAB — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 202444.19₹762.8517.3x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Coral Laboratories Ltd Dividend History

Annual cash dividends paid by CORALAB — dividend yield 0.30%

Financial YearDividends Paid (₹ Cr)
FY 20250.71 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

Coral Laboratories Ltd Quarterly Performance

Latest quarterly metrics for CORALAB — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

-40.96%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-12.70%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

10.26%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

28.24%

Compounded annual net profit growth over 5 years

Coral Laboratories Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for CORALAB — calculated from daily price history

63RSI 14
Neutral — RSI 63

Momentum is balanced — neither overbought nor oversold.

SMA 50
427
▲ Price above SMA 50 — Short-term bullish
SMA 200
468
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
1K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Coral Laboratories Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Coral Laboratories Ltd (CORALAB) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Coral Laboratories Ltd

About CORALAB (Coral Laboratories Ltd)

Coral Laboratories Ltd is a dynamic pharmaceutical company dedicated to developing, manufacturing, and marketing a broad spectrum of healthcare solutions. With a strong commitment ...to quality and innovation, Coralab focuses on creating accessible and affordable medicines that address diverse medical needs across various therapeutic areas. Their state-of-the-art manufacturing facilities adhere to the highest international standards, ensuring the production of safe, effective, and reliable pharmaceutical products. Coralab continuously invests in research and development to stay at the forefront of pharmaceutical advancements and deliver innovative solutions that improve patient outcomes. Coralab's comprehensive product portfolio encompasses a wide range of therapeutic categories, catering to both acute and chronic conditions. These include formulations for managing infectious diseases, such as antibiotics and antifungals, as well as treatments for gastrointestinal disorders, pain management, and respiratory ailments. The company also offers a diverse selection of medications for cardiovascular health, diabetes management, and parasitic infections. With a focus on patient well-being, Coralab is committed to providing healthcare professionals and patients with a wide array of treatment options to enhance their quality of life. Coralab operates with a global perspective, serving markets in India and beyond. Through strategic partnerships and a robust distribution network, the company strives to make its pharmaceutical products accessible to patients worldwide. With a strong emphasis on ethical business practices and a customer-centric approach, Coralab aims to build lasting relationships with healthcare providers and stakeholders. Driven by a passion for improving global health, Coralab continues to expand its reach and impact, delivering high-quality pharmaceutical solutions to meet the evolving needs of patients around the world.

Company Details

Symbol:CORALAB
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Girish Madanlal Dhameja
Whole-Time Director
Ms. Sushma Shashi Kadkade
CFO & Non-Executive Director
Ms. Dhwani Karna Desai
Company Secretary & Compliance Officer

Corporate Events

Recent
Ex-Dividend Date

CORALAB Share Price: Frequently Asked Questions

What is the current share price of Coral Laboratories Ltd?

Coral Laboratories Ltd (CORALAB) trades at ₹506.30 on NSE and BSE. Market cap ₹175.62 (Cr). Educational data only.

What is the P/E ratio of Coral Laboratories Ltd?

Coral Laboratories Ltd has a P/E of 9.95x vs industry average 31.77x.

What is the Bull Run score for Coral Laboratories Ltd?

Coral Laboratories Ltd has a Bull Run score of 55/100 based on 25+ financial parameters.

Does Coral Laboratories Ltd pay dividends?

Coral Laboratories Ltd has a dividend yield of 0.30%. Past dividends don't guarantee future payments.

What is the ROE of Coral Laboratories Ltd?

Coral Laboratories Ltd has ROE of 13.06%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Coral Laboratories Ltd?

Coral Laboratories Ltd has debt-to-equity of 0.00.

Is Coral Laboratories Ltd a good investment?

Bull Run gives Coral Laboratories Ltd a score of 55/100. This is not investment advice — consult a SEBI-registered advisor.